Previous Close | 0.9700 |
Open | 0.9901 |
Bid | 0.9751 x 2200 |
Ask | 1.0100 x 1200 |
Day's Range | 0.9511 - 1.0100 |
52 Week Range | 0.6020 - 3.8100 |
Volume | |
Avg. Volume | 312,433 |
Market Cap | 58.817M |
Beta (5Y Monthly) | 1.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2330 |
Earnings Date | Feb 28, 2023 - Mar 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for SURF
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET. A live audio webcast of the session may be accessed by visiting the Events page
Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders should be happy to see the share price up 25% in the last month...
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.